Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$38.95 USD
-0.92 (-2.31%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $38.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
IONS 38.95 -0.92(-2.31%)
Will IONS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Other News for IONS
JPMorgan biotech analysts hold an analyst/industry conference call
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)
JPMorgan biotech analysts hold an analyst/industry conference call
Ionis Pharmaceuticals Hold Rating: Balancing Promising Data and Market Challenges
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)